A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations, NCT02872714
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
MORE DETAILS ON THIS BLADDER CANCER TRIAL
15228 / INCB 54828-201 / STAR Trial / PI TBD / Open 11-30-2016 / Re-Open 12-11-2017 / Re-Open 2-28-2018 / Call PM 8-29-18
TRIAL AVAILABLE AT THESE LOCATIONS
This is a STAR trial and can be opened at any Location as patients are identified.